Serum endocan role in diagnosis and prognosis of ventilator associated pneumonia

Halim, Ashraf Abd El; Sayed, Manal

doi:10.1016/j.ejcdt.2015.05.015

Cited by 5 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral care of the patients, the use of hand hygiene and glove by the caregivers, and chest physiotherapy were provided at the morning hour every day in accordance with the standard practice of our hospital. We performed serial measurements since we intended to test that Endocan levels had an elevation tendency compared to previous Endocan levels 48 h after and to see the progress of Endocan values in measurements performed 48 h before [1].…”

Section: Material‐methodsmentioning

confidence: 99%

“…When Endocan increase or high fever was determined, anti‐biotherapy was started empirically and when alveolar lavage quantitative culture (>10 5 CFU/ml is accepted as positive) was resulted, antibiotic therapy for pathogen was started. Diagnosis of pneumonia was established in the presence of newly developing transient infiltration, consolidation, cavitation or pleural effusion in the chest radiography and at least 2 of them and with the presence of macroscopically purulent tracheal aspirate and body temperature <36 °C or> 38 °C, and WBC count of <4000/mm3 or >11,000/mm3 [1]. Endocan levels were compared with culture results.…”

Section: Material‐methodsmentioning

confidence: 99%

“…Ventilator‐associated pneumonia (VAP) is defined as lower respiratory tract infections that develop after 48–72 h of intubation in patients admitted to the Intensive Care Unit (ICU) without do not have the history of pneumonia during their hospitalization. VAP is a complication seen as high as 13.6/1000 mechanical ventilator (MV) days, (ranges from 3.5 to 46 infections/1000 MV days in Asian countries) and has a mortality rate of 27–76% [1,2]. The recent studies have showed that delayed diagnosis and thus delayed initiation of appropriate dose and antibiotic therapy increase the mortality [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…The significant potential advantage of biomarkers is that they are semi‐invasive and potentially increase the speed and performance of existing diagnostic methods rather than establishing the diagnosis of the disease. Many biomarkers have been tested to be used in identifying diagnosis and prognosis for patients with suspected or diagnosed VAP [1,5]. However, none of these molecules have been exactly associated with the development of VAP.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Can endocan be a new biomarker in ventilator‐associated pneumonia?

Küpeli

Salcan

Kuzucu

et al. 2018

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Ventilator‐Associated Pneumonia (VAP) is a hospital‐acquired bacterial infection with high incidence and mortality rate. The aim of this study is to investigate the correlation between the Endocan level and development of VAP and whether or not this correlation was correlated with the clinical findings. Demographic data, white blood cell (WBC) count, procalcitonin (PCT), c‐reactive protein (CRP), and fever levels of 60 patients were recorded in serial measurements for 5 days. When there was the presence of fever or elevated Endocan, alveolar lavage culture was taken and chest radiographies were taken. Correlations of the Endocan levels with the culture results and laboratory values were examined. The rate of VAP was found as 10.4/1000 mechanical ventilator days. Endocan levels were significantly higher in patients with VAP (p < 0.05). However, there was no significant difference among PCT, WBC, CRP measurements (p > 0.05). No correlation was found between Endocan levels and PCT, WBC and CRP levels in those with VAP (p > 0.05). A significant correlation was found between the Endocan level and the elevated fever 24 h later (p:0.001). The serum Endocan level on the day 3 had a specificity of 73.3%, a sensitivity of 68.9%, positive predictive value of 44%, and negative predictive value of 88.5% at the cut off level of 9.17 ng/mL. In this study, it was determined that high Endocan levels were associated with the development of VAP. The present study suggested that Endocan can be used as a screening tool for the development of VAP. Clinical Trials.gov ID NCT02916277.

show abstract

Section: Material‐methodsmentioning

confidence: 99%

Section: Material‐methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Can endocan be a new biomarker in ventilator‐associated pneumonia?

Küpeli

Salcan

Kuzucu

et al. 2018

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…Given the paucity of results in chronic kidney disease (CKD) or ADPKD cohorts, direct comparisons between those levels are not available to determine the direct applicability to ADPKD. Reported mean values of plasma Endocan in this study (4.85 µg/dL using the Cusabio assay) are 7-fold higher than the previously published serum levels in a Turkish cohort (control group for a cohort of patients with Behçet disease; mean 0.7 µg/dL using the Bio-Tek Synergy HT assay; Balta et al [9]) but similar to the plasma levels in an Egyptian cohort (4.12 ± 2.9 µg/dL using enzyme-linked immunosorbent assay, LUNGINNOV Systems assay) [10]. Whether the observed differences are simply due to cohort differences, biological sample differences, laboratory methodology, or assay-to-assay variations is unclear.…”

mentioning

confidence: 62%

Hypoxia-Inducible Factor 1α (HIF-1α), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease

Rahbari-Oskoui

Chapman

2018

Am J Nephrol

View full text Add to dashboard Cite

Endocan, sepsis, pneumonia, and acute respiratory distress syndrome

et al. 2018

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) and hospital-acquired pneumonia (HAP) are major problems of public health in intensive care units (ICUs), occurring in 15% of critically ill patients. Among the factors explaining ARDS development, sepsis is known as a frequent cause. Sepsis, ARDS, and HAP increase morbidity, mortality, length of stay in the ICU, and the overall costs of healthcare. The major challenge remains to identify accurately among critically ill patients those at risk of poor outcomes who could benefit from novel therapies. Endocan is released by the pulmonary endothelium in response to local or systemic injury. It inhibits mainly leukocyte diapedesis rather than leukocyte rolling or adhesion to the endothelial cells both in vitro and in vivo. Endocan was evaluated in 25 clinical reports, including 2454 critically ill patients and 452 healthy controls. The diagnostic value of endocan for sepsis or sepsis severity was equal to procalcitonin but its prognostic value was better. A predictive value for postoperative pneumonia was evidenced in two studies, and a predictive value for ARDS in four studies from three independent centers. This review presents an overview of the structure, expression, and functions of endocan. We also hereby summarize the potential applications of endocan in the prediction and prognosis of ARDS and HAP, as well as in the prognosis of sepsis.

show abstract

Serum endocan role in diagnosis and prognosis of ventilator associated pneumonia

Cited by 5 publications

References 21 publications

Can endocan be a new biomarker in ventilator‐associated pneumonia?

Can endocan be a new biomarker in ventilator‐associated pneumonia?

Hypoxia-Inducible Factor 1α (HIF-1α), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease

Endocan, sepsis, pneumonia, and acute respiratory distress syndrome

Contact Info

Product

Resources

About